About Our
Presenting
Companies

Atox Bio
Biological Signal Processing
BioMas
Cardioinspect
Core Dynamics
Diagnostic Technologies
Flowmedic
Immunomed
Izun Pharmaceuticals
Nicast
Optimata
Paieon
Solubest
Tagra
V-Target

Events

Monday, April 18
Maryland
Johns Hopkins University
A & R Building
9601 Medical Center Drive
Rockville, Maryland

Tuesday, April 19
New Jersey
IDT Corporate Office
Newark, NJ

Wednesday, April 20
New York
55 Broad Street
5th floor
New York, NY

Thursday, April 21
Massachussetts
Northeastern University
Boston, MA

Presenting Companies: Optima Ltd.

Core Business / Technology

Optimata is an interdisciplinary, science-based company focusing on the development of simulation and optimization technologies for accelerating drug development in the pharmaceutical industry and for optimizing drug treatment.

Main Markets / Applications

Pharmaceutical developers in cancer, angiogenesis and hematopoietic diseases (Pharma and Biotech companies);

Regulatory agencies;

HMOs;

CROs

Hospitals;

Private clinics.

Main Products Marketed or Under Development

Optimata develops and markets computer-based products for accelerating the critical path in drug development. These products, inclusively named “Virtual Patient Engines”, provide a comprehensive solution for drug development, from the pre-clinical phase through treatment personalization. They include a detailed computer algorithms of pharmacological and biomedical drug-patient Interactive processes, thus enabling drug developers to perform rapid virtual clinical trials and, hence, to forecast optimal mono and combo regimens of cytotoxic, biologic and/or supportive drugs. The company has completed the development of Virtual Patient engines for cancer, angiogenesis-driven and hematopoietic diseases. Optimata’s Virtual Cancer Patient Engine now undergoes multi-center “Phase-I” clinical trials in breast cancer patients.

Uniqueness / Advantage over Existing Products

Optimata’s products, which are “bottom-up” process-driven and labor-intensive, are unique mainly in offering a unified systematic solution for improving predictability and efficiency in drug development, from laboratory concept to clinical implementation. Optimata’s IP products forecast: 1. Phase-I doses, based on animal trials; 2. Optimal Schedules for meeting endpoints, which were predefined by customer; 3. Patient Populations; 4. Personalized treatments. We are aware of only a few other companies in this niche, though their approach differs widely from ours (Gene Networks – identifying intracellular targets; Pharsight – statistical analysis of clinical trials, and Entelos – data-driven probabilistic models for immunologic diseases).

Management

1) Professor Zvia Agur, PhD, Founder, Chairperson and Chief Scientific Officer
2) Guy Malchi, President
3) Dr Levon Arakelyan, PhD, Chief Technology Officer
4) Michael Agur, CFO
5) Dr. Eliahu Braude, MD, Clinical Affairs Officer

Website